---
figid: PMC4845178__kmco-03-01-1029062-g001
figtitle: Dormancy programs and their potential use in patient treatment
organisms:
- NA
pmcid: PMC4845178
filename: kmco-03-01-1029062-g001.jpg
figlink: /pmc/articles/PMC4845178/figure/f0001/
number: F1
caption: Dormancy programs and their potential use in patient treatment. (A) Microenvironmental
  cues such as retinoids and stress signals enforce epigenetic changes in NR2F1 (nuclear
  receptor subfamily 2, group F, member 1) expression and activate an NR2F1-dependent
  dormancy program in local and distant residual tumor cells. This signature is defined
  by the re-expression of genes in the retinoic acid, pluripotency, and cell cycle
  inhibitor pathways. Moreover, NR2F1 maintains active histone markers on SOX9 (SRY
  [sex determining region Y]- box 9) and RARβ (retinoic acid receptor, β) promoters
  in dormant cells. However, at the same time NR2F1 is also responsible for a globally
  repressive chromatin state. Lastly, all trans retinoic acid (atRA) in combination
  with azacytidine (aza) enforces a long-sustained NR2F1-induced dormancy program.
  H3-PTMs, histone 3-post-translational modifications; MRD, minimal residual disease.
  (B) Possible therapeutic scenarios for patients with long-term MRD. Disseminated
  tumor cells (DTCs) collected from bone marrow (BM) of M0 stage patients (distant
  metastases are not detected) could be analyzed to determine their dormant or active
  status and select the appropriate therapeutic action. For example, if DTCs carry
  a dormancy signature (NR2F1high/NR2F1 targetshigh) either dormancy maintaining therapy
  could be applied or therapies that eliminate these cells could be used (lower part
  of the panel); if DTCs carry a signature indicative of reactivation (NR2F1low/NR2F1
  targetslow) then the azacytidine+atRA therapy that we propose here may serve to
  convert these residual tumor cells back to dormancy. This combination might also
  benefit from the addition of inhibitors of the mitogen-activated protein kinase
  1 (MAPK1) pathway (1). DTCs from BM aspirates could be tested for restoration of
  dormancy biomarkers and to examine the long-lasting treatment efficacy over years.
  Patients under this scenario would be considered in remission. Alternatively, the
  design of treatments that allow terminal differentiation of residual tumor cells
  would entirely prevent the reawakening of DTCs and induce an extended long-term
  remission phase (2).
papertitle: Dormancy programs as emerging antimetastasis therapeutic alternatives.
reftext: Maria Soledad Sosa. Mol Cell Oncol. 2016 Jan;3(1):e1029062.
year: '2016'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8323082
figid_alias: PMC4845178__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC4845178__F1
ndex: f244da61-df14-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4845178__kmco-03-01-1029062-g001.html
  '@type': Dataset
  description: Dormancy programs and their potential use in patient treatment. (A)
    Microenvironmental cues such as retinoids and stress signals enforce epigenetic
    changes in NR2F1 (nuclear receptor subfamily 2, group F, member 1) expression
    and activate an NR2F1-dependent dormancy program in local and distant residual
    tumor cells. This signature is defined by the re-expression of genes in the retinoic
    acid, pluripotency, and cell cycle inhibitor pathways. Moreover, NR2F1 maintains
    active histone markers on SOX9 (SRY [sex determining region Y]- box 9) and RARβ
    (retinoic acid receptor, β) promoters in dormant cells. However, at the same time
    NR2F1 is also responsible for a globally repressive chromatin state. Lastly, all
    trans retinoic acid (atRA) in combination with azacytidine (aza) enforces a long-sustained
    NR2F1-induced dormancy program. H3-PTMs, histone 3-post-translational modifications;
    MRD, minimal residual disease. (B) Possible therapeutic scenarios for patients
    with long-term MRD. Disseminated tumor cells (DTCs) collected from bone marrow
    (BM) of M0 stage patients (distant metastases are not detected) could be analyzed
    to determine their dormant or active status and select the appropriate therapeutic
    action. For example, if DTCs carry a dormancy signature (NR2F1high/NR2F1 targetshigh)
    either dormancy maintaining therapy could be applied or therapies that eliminate
    these cells could be used (lower part of the panel); if DTCs carry a signature
    indicative of reactivation (NR2F1low/NR2F1 targetslow) then the azacytidine+atRA
    therapy that we propose here may serve to convert these residual tumor cells back
    to dormancy. This combination might also benefit from the addition of inhibitors
    of the mitogen-activated protein kinase 1 (MAPK1) pathway (1). DTCs from BM aspirates
    could be tested for restoration of dormancy biomarkers and to examine the long-lasting
    treatment efficacy over years. Patients under this scenario would be considered
    in remission. Alternatively, the design of treatments that allow terminal differentiation
    of residual tumor cells would entirely prevent the reawakening of DTCs and induce
    an extended long-term remission phase (2).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TGFB2
  - BMP7
  - RARA
  - RARB
  - CRK
  - MAPK14
  - MAPK1
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - SOX9
  - NR2F1
  - NANOG
  - SOX2
  - IFI27
  - PSMD9
  - ZNRD2
  - DCTN6
  - TMED7
  - H3P23
  - MS
  - PTMS
  - TYMS
  - PYCARD
  - CDKN2A
  - H3P10
  - Azacytidine
---
